Bladder Preservation and Biomarker Challenges in MIBC

In “Bladder Preservation and Biomarker Challenges in MIBC,” our panel explores the evolving role of imaging and molecular biomarkers in assessing treatment response and guiding bladder-sparing strategies for muscle-invasive bladder cancer (MIBC). The expert urologic oncology faculty discuss the current limitations of bladder MRI, circulating tumor DNA (ctDNA), and urinary tumor DNA (utDNA) in accurately distinguishing residual disease from treatment-related inflammation following perioperative therapy.

Throughout the discussion, the panelists examine the growing interest in using biomarkers to identify patients who may potentially avoid radical cystectomy after strong responses to systemic therapy. The faculty review emerging data evaluating utDNA and ctDNA as predictive tools for pathologic complete response, while emphasizing that current biomarker performance remains insufficient to reliably guide bladder preservation decisions in routine clinical practice.

The panel also highlights the challenges associated with occult residual disease and understaging in patients who appear to have complete clinical responses following perioperative therapy. In addition, the discussion explores how inflammatory and desmoplastic changes after systemic treatment may complicate MRI interpretation and limit the accuracy of imaging-based response assessment.

Finally, the faculty emphasize that although biomarker-driven bladder preservation strategies remain an exciting future direction, significant unanswered questions remain regarding recurrence risk, disease biology, and long-term outcomes in patients managed without radical cystectomy. The panel concludes that continued research and improved predictive tools will be essential before bladder-sparing approaches can be more broadly adopted in the evolving management of MIBC.

Our next episode, “Perioperative Therapy and Surgical Recovery in MIBC,” features the panelists discussing how newer systemic therapies are influencing tissue healing, operative recovery, and postoperative outcomes following radical cystectomy in muscle-invasive bladder cancer. The panel also highlights evolving perspectives on surgical safety, urinary diversion outcomes, and recovery in the perioperative era of MIBC.